Kitchener-Waterloo-based Deep Genomics, an artificial intelligence (AI) therapeutics company, has tapped Ferdinand Massari, as its chief medical officer.

Massari is based in Boston and will oversee clinical development and contribute to expanding the company’s AI platform and therapeutic portfolio.

Massari joins Deep Genomics with over 30 years’ experience in biotech.

Massari comes to Deep Genomics with over 30 years of experience in the pharmaceutical and biotech industries. He has been the CMO or most senior medical and development lead at over a dozen companies in the United States and Europe.

Most recently, Massari helped found Kintai Therapeutics and built a team of over 60 researchers in computational biology, metabolomics, anaerobic microbiology, and medicinal chemistry for that startup

Massari also served as vice president of worldwide medical affairs at Pfizer, vice president of Pharmacia, and director at Merck. Massari has led teams that have registered treatments for rare diseases as well as therapies for resistant bacterial infections and HIV.

“I have seen many biotech companies tout the value of computational biology and artificial intelligence,” said Massari. “Deep Genomics is the first company I’ve encountered in which I see a direct connection between their AI systems and faster and more accurate production of preclinical and clinical candidates. I am excited to join this interdisciplinary team.”

StartUp HERE Toronto is a publishing partner of Betakit and this article was originally published on their site.